NVCT Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 3.38%, SMA50 6.79%, SMA200 20.35%). The stock’s 14-day RSI is 58.7 (neutral), while the ATR of 0.46 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -22.4% below its high and over 61.08% above its low. Average 10-day trading volume of 56.15 thousand shares is in line with the 3-month average of 58.04 thousand, indicating normal recent market interest.

Nuvectis Pharma, Inc. generated EPS of -$1.28 over the past year. Five-year average earnings growth is -340.28%. Wall Street analysts project EPS growth of 4.33% annually over the next five years. The latest quarter delivered EPS of -$0.44. The next quarter is forecast at -$0.31. Next year's EPS is expected at -$7.03. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $10.00 to $10.00. The high target offers 14.55% upside. The low target suggests 14.55% downside. The mean target is $10.00. This offers 14.55% upside. Nuvectis Pharma, Inc. earnings surprise history is a mixed track record. The quarter that ended November 04, 2025, missed forecasts by 83.33%. The prior quarter beat by 20.0%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in August 06, 2024.

Nuvectis Pharma, Inc. (NASDAQ:NVCT) closed at $8.38 USD, losing -$0.12 (-1.41%) from the previous close of $8.50. The stock is currently mid-range between its 52-week high and low $5.55 and $11.52. With a market capitalization of about $222.00 million, Nuvectis Pharma, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.21). Key stats such as the average daily volume over the past year has been around 57.92 thousand shares, volume is running light vs its 52-week average. Headquartered in Fort Lee, NJ, Nuvectis Pharma, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Ron Bentsur, the company employs approximately 13 people and listed since February 04, 2022. Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology.

Nuvectis Pharma, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.45. This means the shares are trading above this model’s fair value.

Nuvectis Pharma, Inc. has 25.46 million shares outstanding. The public float is 14.54 million shares, elevated short interest at 6.61% of float. This equals 1.02 million shares. The short ratio is 4.85 days. Institutional investors hold 24.62% of the float. Insiders own 43.55%. BENTSUR RON holds 3.53 million shares, Mosseri Marlio Charles has 3.14 million shares and Poradosu Enrique has 1.51 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Nuvectis Pharma, Inc. (NASDAQ:NVCT) shares are flat 7.42% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Nuvectis Pharma, Inc. trading at a premium to the broader market with a P/E of -7.17. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $18.00, suggesting 106.19% upside. Our AI forecast model points to short-term weakness (-6.87% over two weeks), a medium-term fall (-37.46% over three months), and a longer-term gain (106.99% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Nuvectis Pharma, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -6.87%, with price expected at $8.13 by April 28, 2026, within a range of $7.65 to $8.62 3-Month Outlook: Projected fall of -37.46%, reaching $5.46 by July 13, 2026, with a range of $4.89 to $5.98. 1-Year Outlook: Projected gain of 106.99%, with price at $18.07 by April 14, 2027, within a range of $0.00 to $28.45.

Nuvectis Pharma, Inc. trades at a P/E ratio of -7.17, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 10.3 reflecting a rich premium to book value. The P/FCF stands at -14.39, also above market averages. Compared to sector medians, Nuvectis Pharma, Inc. P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.